Clinical trials have also showed the significant clinical value of PLD combined with carboplatin as a first-line refractory recurrent ovarian cancer chemotherapy regimen.294 Kelm et al. found that Withaferin A treatment reduced plasma angiotensin II and angiotensin II type 1 receptor-induced inflammatory factors expression in tumor-bearing mice, decreased cardiac fibrosis, and enhanced cardiac function, suggesting that it could play a protective role in cardiac remodeling and dysfunction caused by ovarian cancer xenotransplantation.295 PDE10A is expressed in human tumor cell lines. The gene discussed is PDE10A; the disease is ovarian carcinoma.